Opus Genetics Announces Results From Low-Dose Cohort 1 Of BIRD-1, Ongoing Phase 1/2 Clinical Trial Evaluating Opgx-BEST1 Showing Favorable Safety, Tolerability Profile With No Serious Adverse Events Or Dose-Limiting Toxicities Observed
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual
Opus Genetics tested a new medicine on five people, and it was safe with no big problems. When a medicine's first tests go smoothly and people feel better, it's a good sign the company might be on the right track.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.